Immunogenicity and Safety Evaluation of Inactivated Hepatitis A Vaccine in Healthy Adults and Children

This clinical trial is all about evaluating the safety and effectiveness of a vaccine called Healive®, which is designed to prevent hepatitis A in healthy adults and children aged 1 year and older. The study is particularly interested in understanding how well the vaccine works in two different age groups: adults (16 years and above) and children (1 to less than 16 years). The importance of this study lies in its potential to provide a reliable solution for preventing hepatitis A, a contagious liver disease, in a broad age range. The trial involves 680 participants in total. Adults will receive a 1 mL dose of Healive®, while children will receive either a 0.5 mL dose of Healive® or a comparable vaccine, Avaxim®. Participants in the children's group will be randomly assigned to receive one of these two vaccines. Everyone involved will receive two doses of their assigned vaccine, six months apart. The study's primary focus is to measure the percentage of participants who develop protective antibodies against hepatitis A 30 days after their second vaccination. This helps researchers understand how well the vaccine prompts the body's immune response.